Zhong et al., 2025 - Google Patents
The Encapsulation Strategies for Targeted Delivery of Probiotics in Preventing and Treating Colorectal Cancer: AZhong et al., 2025
- Document ID
- 176619297745895348
- Author
- Zhong H
- Jiang J
- Hussain M
- Zhang H
- Chen L
- Guan R
- Publication year
External Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhong et al. | The encapsulation strategies for targeted delivery of probiotics in preventing and treating colorectal cancer: A review | |
| Xie et al. | Modified prebiotic-based “shield” armed probiotics with enhanced resistance of gastrointestinal stresses and prolonged intestinal retention for synergistic alleviation of colitis | |
| Liu et al. | Biomaterials coating for on-demand bacteria delivery: Selective release, adhesion, and detachment | |
| Peng et al. | Gastrointestinal microenvironment responsive nanoencapsulation of probiotics and drugs for synergistic therapy of intestinal diseases | |
| Liu et al. | Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges | |
| Li et al. | Intestinal delivery of probiotics: materials, strategies, and applications | |
| Hu et al. | Polyphenolic nanoparticle-modified probiotics for microenvironment remodeling and targeted therapy of inflammatory bowel disease | |
| Priya et al. | Enhanced survival of probiotic Lactobacillus acidophilus by encapsulation with nanostructured polyelectrolyte layers through layer-by-layer approach | |
| AU2008337269B2 (en) | Formulations comprising exine shells | |
| Zhang et al. | Advanced nanomedicine: redefining therapeutic paradigms for inflammatory bowel disease | |
| Yang et al. | Calcium tungstate microgel enhances the delivery and colonization of probiotics during colitis via intestinal ecological niche occupancy | |
| Kuang et al. | Triggerable prodrug nanocoating enables on-demand activation of microbial and small-molecular therapeutics for combination treatment | |
| Hu et al. | Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances | |
| Han et al. | Oral delivery of probiotics using single‐cell encapsulation | |
| Cui et al. | Functional ginger-derived extracellular vesicles-coated ZIF-8 containing TNF-α siRNA for ulcerative colitis therapy by modulating gut microbiota | |
| Chen et al. | Chitosan-based oral colon-specific delivery systems for polyphenols: recent advances and emerging trends | |
| Wu et al. | Preparation of oral core–shell zein nanoparticles to improve the bioavailability of glycyrrhizic acid for the treatment of ulcerative colitis | |
| Li et al. | Orally administrated olsalazine-loaded multilayer pectin/chitosan/alginate composite microspheres for ulcerative colitis treatment | |
| Zhang et al. | Carbohydrate polymer-based carriers for colon targeted delivery of probiotics | |
| WO2024035781A1 (en) | Mucoadhesive probiotic backpacks with ros nano-scavengers enhance the bacteriotherapy for inflammatory bowel diseases | |
| Bal et al. | Antiproliferative and apoptotic effects of olive leaf extract microcapsules on MCF-7 and A549 cancer cells | |
| Choudhary et al. | Microencapsulation of probiotic Streptococcus salivarius LAB813 | |
| Su et al. | Harnessing Akkermansia muciniphila membrane coating for probiotic therapy in inflammatory bowel disease | |
| Wang et al. | Advancing polyphenol-based nanomedicine for inflammatory bowel disease: challenges and opportunities | |
| Guan et al. | Therapeutic systems based on natural gut microbiota modulators: the latest advances in the treatment of inflammatory bowel disease |